Neuropeptide Y and Related Peptides Fall Short as Prostate Cancer Biomarkers Compared to PSA

What the researchers found

Using liquid chromatography tandem mass spectrometry — a highly specific measurement technique — the researchers analyzed NPY, its precursors, and metabolites in plasma and tissue from 181 patients. NPY and related peptides were less accurate than PSA alone at diagnosing significant prostate cancer.

Combining multiple NPY-related peptides in a stepwise diagnostic approach did not improve diagnostic performance in a way that would benefit patients. There was a limited signal suggesting NPY might add value for patients with PSA in the 4–9 ng/ml gray zone, but this finding lacked statistical strength.

Why it matters

PSA testing for prostate cancer is far from perfect — it produces many false positives and can miss significant cancers. There has been strong interest in finding better biomarkers, and earlier studies using less precise methods suggested NPY might be a candidate. This rigorous study using gold-standard mass spectrometry shows that NPY does not improve on PSA, which is important for redirecting research efforts toward more promising biomarker candidates.

How the study worked

The study analyzed blood plasma and tissue samples from 181 patients using liquid chromatography tandem mass spectrometry (LC-MS/MS), which is more specific than the immunoassays used in earlier NPY research. The researchers measured concentrations of NPY, its precursors, and metabolites, then compared the diagnostic accuracy of these peptides against standard PSA testing, both individually and in combination with other clinical variables like prostate volume and age.

What this study cannot tell us

The sample size of 181 patients, while reasonable, may not have been large enough to detect subtle diagnostic benefits of NPY in specific subgroups. The study acknowledges that the potential benefit in the PSA gray zone (4–9 ng/ml) was limited in statistical power. Earlier positive results used immunoassays, and the discrepancy with LC-MS/MS findings raises questions about which method better captures clinically relevant NPY forms.

How to read the evidence

This is a clinical diagnostic accuracy study with 181 patients using a gold-standard analytical method. While it provides strong evidence against NPY as a standalone biomarker, it is a single-center study and the subgroup findings lack statistical power.

When this study was published

Published in 2024, this is a recent study that uses modern mass spectrometry methods to reassess older immunoassay-based findings about NPY in prostate cancer diagnosis.

The bigger picture

The search for better prostate cancer biomarkers is a major focus in urology research. Previous immunoassay studies had generated excitement about NPY as a diagnostic peptide, but this study — using a more precise analytical method — suggests those earlier results may have been overly optimistic. This is a cautionary example of how measurement technique matters in biomarker research, and it narrows the field of peptide-based diagnostic candidates for prostate cancer.

Questions still open

• Could different forms or fragments of NPY still prove useful as biomarkers in specific patient subgroups?
• Why did earlier immunoassay studies show more promising results — were they detecting different molecular forms of NPY?
• Are there other endogenous peptides that might outperform PSA as prostate cancer biomarkers?

Common questions

Read the original research

Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection.

European urology open science, 66, 12-15

Citation

Maurer, Jonathan; Eugster, Philippe J; Collins, Kiana; Vocat, Céline; Oke, Jason; Nicholson, Brian; Rakauskas, Arnas; Grouzmann, Eric; Valerio, Massimo. (2024). Neuropeptide Y and Derivates Are Not Ready for Prime Time in Prostate Cancer Early Detection.. European urology open science, 66, 12-15. https://doi.org/10.1016/j.euros.2024.06.008